Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bicara Therapeutics Inc. - Common Stock
(NQ:
BCAX
)
26.40
-0.70 (-2.58%)
Streaming Delayed Price
Updated: 11:38 AM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
100,439
Open
26.85
Bid (Size)
26.30 (100)
Ask (Size)
26.44 (100)
Prev. Close
27.10
Today's Range
25.88 - 26.85
52wk Range
9.570 - 30.99
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Top movers in Friday's after hours session
↗
July 31, 2026
Via
Chartmill
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
July 28, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Performance
YTD
+61.2%
+61.2%
1 Month
-9.7%
-9.7%
3 Month
+16.2%
+16.2%
6 Month
+57.5%
+57.5%
1 Year
+137.4%
+137.4%
More News
Read More
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
↗
June 13, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Results Highlight Clinical Progress as EPS Misses Estimates
↗
May 11, 2026
Via
Chartmill
Bicara (BCAX) Q4 2025 Earnings Transcript
↗
June 01, 2026
Via
The Motley Fool
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
↗
May 22, 2026
Via
MarketBeat
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
May 21, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
↗
May 15, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
↗
May 15, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
↗
May 14, 2026
Via
MarketBeat
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara (BCAX) Q1 2026 Earnings Transcript
↗
May 11, 2026
Via
The Motley Fool
Bicara Therapeutics Q1 Earnings Call Highlights
↗
May 11, 2026
Via
MarketBeat
Topics
Earnings
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 11, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Chief Medical Officer Sells 5,500 Shares for $126,000
↗
May 04, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
May 04, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 03, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
↗
April 01, 2026
Via
Chartmill
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy?
↗
March 30, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics CEO Quietly Sold Shares. Her 339,000-Share Stake Speaks Louder.
↗
March 26, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 23, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 04, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 26, 2026
From
Bicara Therapeutics Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is Bicara Therapeutics Inc. - Common Stock publicly traded?
Yes, Bicara Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Bicara Therapeutics Inc. - Common Stock trade on?
Bicara Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Bicara Therapeutics Inc. - Common Stock?
The ticker symbol for Bicara Therapeutics Inc. - Common Stock is BCAX on the Nasdaq Stock Market
What is the current price of Bicara Therapeutics Inc. - Common Stock?
The current price of Bicara Therapeutics Inc. - Common Stock is 26.40
When was Bicara Therapeutics Inc. - Common Stock last traded?
The last trade of Bicara Therapeutics Inc. - Common Stock was at 08/03/26 11:38 AM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
